PRO 140
Sponsors
CytoDyn, Inc., Drexel University
Conditions
Graft Vs Host DiseaseHIVHIV InfectionsHIV-1-infectionHuman Immunodeficiency VirusHuman Immunodeficiency Virus (HIV)
Phase 1
Phase 2
PRO 140 by IV Administration in Adults With HIV-1 Infection
CompletedNCT00613379
Start: 2007-12-31End: 2008-08-31Updated: 2016-07-15
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
WithdrawnNCT01272258
Start: 2013-12-31End: 2017-02-28Updated: 2017-02-02
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
CompletedNCT02175680
Start: 2014-04-16End: 2015-02-02Updated: 2023-04-14
PRO 140 for Human Immunodeficiency Virus Infection
WithdrawnNCT02257788
Start: 2014-09-30End: 2015-02-28Updated: 2017-03-09
PRO 140 for Human Immunodeficiency Virus
WithdrawnNCT02438345
Start: 2012-11-30End: 2015-02-28Updated: 2017-03-03
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
CompletedNCT02483078
Start: 2015-10-31End: 2018-07-31Updated: 2022-11-03
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
TerminatedNCT02737306
Start: 2017-05-14End: 2021-09-30Updated: 2024-03-12
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
TerminatedNCT02990858
Start: 2016-11-03End: 2022-07-10Updated: 2025-11-12
PRO 140 in Treatment-Experienced HIV-1 Subjects
CompletedNCT03902522
Start: 2018-06-25End: 2020-05-18Updated: 2025-09-16